MEPSEVII™ (vestronidase alfa-vjbk) was found to be effective in clinical trials

MEPSEVII™ (vestronidase alfa-
vjbk)
was found to be effective in clinical trials

Patients with confirmed MPS VII who received MEPSEVII were studied for up to 164 weeks. The effectiveness of MEPSEVII was determined using several tests, including:

Image

Six-minute walk test (6MWT),
which measures how far someone can walk in 6 minutes. It is an effective way of measuring how well the different systems in the body work together

Image

Breathing ability,
which is measured to see how healthy the respiratory system is

Image

Liver and spleen size,
which measures whether these organs are of normal or abnormal size

Due to the nature of MPS VII and the differences in the patients in this trial, you should talk with your doctor about what you may expect from treatment with MEPSEVII

In clinical trials, some patients who took MEPSEVII experienced improvement or maintained walking distance, breathing ability, or organ size

After 120 weeks, 10 out of 12 patients who took MEPSEVII had improved or maintained walking distance

At the end of 120 weeks, 3 of the 10 patients had at least a 60-meter (197-foot) improvement in distance walked compared to when they started treatment with MEPSEVII

Of the 3 patients who improved on their 6MWT, 2 patients improved in their balance and overall movement abilitya

aDetermined using the Bruininks-Oseretsky Test of Motor Proficiency (BOT-2).

At the end of 120 weeks, 7 of the 10 patients had maintained their distance walked compared to when they started treatment with MEPSEVII

Patient 10 did not use an assistive device at the start of the study but started using an assistive device at Week 8 of his treatment. Patients 6 and 9 consistently used an assistive device at all visits. A solid line indicates the unassisted assessments and a dotted line indicates the assisted assessments.

After 120 weeks, 10 out of 12 patients who took MEPSEVII had improved or maintained walking distance

At the end of 120 weeks, 3 of the 10 patients had at least a 60-meter (197-foot) improvement in distance walked compared to when they started treatment with MEPSEVII

Of the 3 patients who improved on their 6MWT, 2 patients improved in their balance and overall movement abilitya

aDetermined using the Bruininks-Oseretsky Test of Motor Proficiency (BOT-2).

At the end of 120 weeks, 7 of the 10 patients had maintained their distance walked compared to when they started treatment with MEPSEVII

Patient 10 did not use an assistive device at the start of the study but started using an assistive device at Week 8 of his treatment. Patients 6 and 9 consistently used an assistive device at all visits. A solid line indicates the unassisted assessments and a dotted line indicates the assisted assessments.

Breathing ability

After 120 weeks of exposure to MEPSEVII, 1 out of 3 patients showed:

21% improvement in breathing abilitya compared to the start of the study

The same patient showed:

105-meter improvement (344 feet) in walking distance (6MWT) compared to the start of the study

aAs measured by forced vital capacity (FVC), which is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.

All patients treated with MEPSEVII experienced a reduction of urinary of GAGs, which was sustained with continued treatment.

What is MEPSEVII?
MEPSEVII is used to treat children and adults with Mucopolysaccharidosis VII (MPS VII, Sly syndrome). The effect of MEPSEVII on the central nervous system (brain and spinal cord) symptoms of MPS VII has not been determined.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about MEPSEVII?
  • A severe allergic reaction called anaphylaxis has occurred with MEPSEVII treatment, as early as the first dose.
  • Your doctor will monitor you closely for symptoms of an allergic reaction while you are receiving MEPSEVII and for 60 minutes after your injection.
  • Your doctor will immediately discontinue the MEPSEVII infusion if you experience anaphylaxis.
  • Your doctor should talk to you about the signs and symptoms of anaphylaxis and about getting medical treatment if you have symptoms after leaving the doctor’s office or treatment center.
What are the possible side effects of MEPSEVII?
  • The most common side effects of MEPSEVII are:
    • Leakage of MEPSEVII into the surrounding tissue during infusion
    • Diarrhea
    • Rash
    • Severe allergic reaction (anaphylaxis)
    • Infusion site swelling
    • Swelling around the infusion site
    • Severe itching of the skin
  • One patient experienced a seizure during a fever while taking MEPSEVII.
Before receiving MEPSEVII, tell your doctor about all of your medical conditions, including if you:
  • are pregnant, think you may be pregnant, or plan to become pregnant. There is not enough experience to know if MEPSEVII may harm your unborn baby.
  • are breastfeeding or plan to breastfeed. There is not enough experience to know if MEPSEVII passes into your breast milk. Talk with your doctor about the best way to feed your baby while you receive MEPSEVII.

These are not all the possible side effects of MEPSEVII. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Ultragenyx at 1-888-756-8657.

Please see full Prescribing Information for additional Important Safety Information including serious side effects.